Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study

Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study

(2021) Ying Cheng et al.   Targeted Oncology

Angiogenesis inhibitor plus erlotinib versus erlotinib alone as first-line for advanced non-small cell lung-cancer harboring EGFR mutation.

(2020) Thierry Landre et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers

(2020) Helena A. Yu et al.   JAMA Oncology

Clinical impact of uncommon epidermal growth factor receptor exon 19 insertion-deletion variants on epidermal growth factor receptor-tyrosine kinase inhibitor efficacy in non-small-cell lung cancer

(2020) Xingzhou Peng et al.   EUROPEAN JOURNAL OF CANCER

Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial

(2019) Haruhiro Saito et al.   LANCET ONCOLOGY

EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases

(2019) Tao Jiang et al.   EUROPEAN JOURNAL OF CANCER

P2.14-52 The Results from Plasma EGFR Mutation Analysis in NEJ026 Study

(2019) T. Fukuhara et al.   Journal of Thoracic Oncology

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

(2019) Suresh S. Ramalingam et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

(2019) Kazuhiko Nakagawa et al.   LANCET ONCOLOGY

Overview of current systemic management of EGFR-mutant NSCLC

(2018) W -H Hsu et al.   ANNALS OF ONCOLOGY

A Convergence-Based Framework for Cancer Drug Resistance

(2018) David J. Konieczkowski et al.   CANCER CELL

Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when?

(2018) Nicolas Girard   Future Oncology

Bevacizumab Reduces S100A9-Positive MDSCs Linked to Intracranial Control in Patients with EG FR -Mutant Lung Adenocarcinoma

(2018) Po-Hao Feng et al.   Journal of Thoracic Oncology

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

(2018) Jean-Charles Soria et al.   NEW ENGLAND JOURNAL OF MEDICINE

Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial

(2018) Zhijie Wang et al.   Lancet Respiratory Medicine

Osimertinib versus standard-of-care EGFR-TKI as first-line treatment in patients with EGFRm advanced NSCLC: FLAURA Asian subset

(2018) Byoung Chul Cho et al.   Journal of Thoracic Oncology

Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

(2017) Nasser Hanna et al.   JOURNAL OF CLINICAL ONCOLOGY

Capture-Based Targeted Ultradeep Sequencing in Paired Tissue and Plasma Samples Demonstrates Differential Subclonal ctDNA-Releasing Capability in Advanced Lung Cancer

(2017) Xiaowei Mao et al.   Journal of Thoracic Oncology

Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma

(2016) A. Ilhan-Mutlu et al.   MOLECULAR CANCER THERAPEUTICS

First-line erlotinib versus gemcitabine/cisplatin in patients with advancedEGFRmutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study

(2015) Y.-L. Wu et al.   ANNALS OF ONCOLOGY

Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study

(2015) B. Besse et al.   CLINICAL CANCER RESEARCH

Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: a meta-analysis

(2015) Miaomiao Sheng et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Impact of bevacizumab in combination with erlotinib onEGFR-mutated non-small cell lung cancer xenograft models with T790M mutation orMETamplification

(2015) Koh Furugaki et al.   INTERNATIONAL JOURNAL OF CANCER

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study

(2014) Takashi Seto et al.   LANCET ONCOLOGY

Bevacizumab and central nervous system (CNS) hemorrhage

(2013) Nathalie Letarte et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer

(2013) T. Ciuleanu et al.   LUNG CANCER

Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trial (SAKK 19/05)

(2012) Francesco Zappa et al.   LUNG CANCER

Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial

(2011) Roy S Herbst et al.   LANCET

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

(2011) Caicun Zhou et al.   LANCET ONCOLOGY

Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis

(2011) Annette K. Larsen et al.   PHARMACOLOGY & THERAPEUTICS

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

(2011) L. V. Sequist et al.   Science Translational Medicine

Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

(2010) M. Reck et al.   ANNALS OF ONCOLOGY

Somatic Mutations of the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor and Tyrosine Kinase Inhibitor Response to TKIs in Non-small Cell Lung Cancer: An Analytical Database

(2010) Samuel Murray et al.   Journal of Thoracic Oncology

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

(2010) Makoto Maemondo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance

(2009) G. N. Naumov et al.   CLINICAL CANCER RESEARCH

Safety of Bevacizumab in Patients With Non–Small-Cell Lung Cancer and Brain Metastases

(2009) Mark A. Socinski et al.   JOURNAL OF CLINICAL ONCOLOGY

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

(2009) Tetsuya Mitsudomi et al.   LANCET ONCOLOGY

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bevacizumab and Erlotinib: A Promising New Approach to the Treatment of Advanced NSCLC

(2008) R. S. Herbst et al.   ONCOLOGIST